Last reviewed · How we verify

Canadian Cancer Trials Group — Portfolio Competitive Intelligence Brief

Canadian Cancer Trials Group pipeline: 0 marketed, 0 filed, 5 Phase 3, 10 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 10 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intermittent PD-1 inhibitor therapy Intermittent PD-1 inhibitor therapy phase 3 PD-1 inhibitor PD-1 Oncology
ADT ADT phase 3 Androgen deprivation therapy Androgen receptor / testosterone production Oncology
Darolutamide (BAY 1841788) Darolutamide (BAY 1841788) phase 3 Non-steroidal androgen receptor antagonist Androgen receptor (AR) Oncology
Capox Capox phase 3 Other
Continuous PD-1 inhibitor therapy Continuous PD-1 inhibitor therapy phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ono Pharmaceutical Co. Ltd · 2 shared drug classes
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  5. Addpharma Inc. · 2 shared drug classes
  6. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 2 shared drug classes
  7. Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
  8. AIO-Studien-gGmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Canadian Cancer Trials Group:

Cite this brief

Drug Landscape (2026). Canadian Cancer Trials Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/canadian-cancer-trials-group. Accessed 2026-05-16.

Related